VEGFA and atherosclerosis: Larger studies are warranted to evaluate the potential additive cardiovascular risks from agents such as immune checkpoint inhibitors, which may accelerate atherosclerosis [60], and VEGF inhibitors, which have been associated with hypertension [61].